CD274 and urothelial carcinoma: PD‐1 mAb therapy with pembrolizumab and nivolumab have had great clinical success for a variety of solid tumors and have received Food and Drug Administration (FDA) approval for the treatment of multiple solid tumors, including melanoma, non‐small‐cell lung cancer, urothelial carcinoma, and renal cell cancer.15, 16 Atezolizumab is an anti‐PD‐L1 monoclonal antibody that can also disrupt the interaction between PD‐1 and its ligands,17 and has been approved for the treatment of non‐small‐cell lung cancer and urothelial carcinoma.18